Ironwood files Form 144 for proposed RSU share sales

Ironwood Pharmaceuticals, Inc. submitted a Form 144 notice reporting proposed sales of Class A Common Stock tied to previously granted restricted stock unit awards.

Accepted by SEC EDGAR 02/20/2026 - 04:44 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ironwood Pharmaceuticals, Inc. submitted a Form 144 notice reporting proposed sales of Class A Common Stock tied to previously granted restricted stock unit awards. The excerpt lists example lots of 20,362, 17,467, 13,606, and 33,334 shares associated with award grant dates from 03/02/2022 through 02/10/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ironwood's (IRWD) Form 144 report?

It reports proposed sales of Class A Common Stock tied to restricted stock unit awards. The excerpt lists award grant dates and example lot sizes of 20,362; 17,467; 13,606; and 33,334 shares.

Are the shares already sold according to the Form 144?

No. Form 144 is a notice of proposed sale, not a confirmation of completion. The filing lists intended sale lots linked to RSU grants dated 03/02/2022–02/10/2025.

Do the listed RSU grant dates affect when sales can occur for IRWD?

The grant dates identify the awards converted or subject to sale reporting. The excerpt shows grant dates from 03/02/2022 to 02/10/2025, which relate to vesting and eligibility timing.

Does the Form 144 disclose aggregate proceeds or sale method for IRWD shares?

No. The provided excerpt lists award lots and grant dates but does not state aggregate proceeds or the distribution method for the proposed sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001808509
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IRONWOOD PHARMACEUTICALS INC
SEC File Number	001-34620
Address of Issuer	100 SUMMER STREET, SUITE 2300 BOSTON MASSACHUSETTS 02110
Phone	617-621-7722
Name of Person for Whose Account the Securities are To Be Sold	Shetzline Michael
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	E Trade Securities LLC 3 Edison Drive Alpharetta GA 30005	29937	138009.57	162678647	02/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	03/02/2022	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			20362	03/02/2022	N/A
Class A Common Stock	03/08/2023	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			17467	03/08/2023	Nasdaq
Class A Common Stock	02/12/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			13606	02/12/2024	Nasdaq
Class A Common Stock	02/10/2025	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			33334	02/10/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold to cover taxes from the vesting of stock awards granted by the Issuer.
Date of Notice	02/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Michael Shetzline
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)